Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Zhejiang Sci-Tech University · The First People's Hospital of Xiaoshan District, Hangzhou · +4 more institutions
Abstract
Vascular endothelial growth factors (VEGF), Vascular endothelial growth factor receptors (VEGFR) and their downstream signaling pathways are promising targets in anti-angiogenic therapy. They constitute a crucial system to regulate physiological and pathological angiogenesis. In the last 20 years, many anti-angiogenic drugs have been developed based on VEGF/VEGFR system to treat diverse cancers and retinopathies, and new drugs with improved properties continue to emerge at a fast rate. They consist of different molecular structures and characteristics, which enable them to inhibit the interaction of VEGF/VEGFR, to inhibit the activity of VEGFR tyrosine kinase (TK), or to inhibit VEGFR downstream signaling. In…
Citation impact
- FWCI
- 24.48
- Percentile
- 100%
- References
- 229
Authors
5- LWLei WangCorresponding
Zhejiang Sci-Tech University, The First People's Hospital of Xiaoshan District, Hangzhou
- WLWang‐Qing Liu
Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Sorbonne Paris Cité
- SBSylvain Broussy
Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Sorbonne Paris Cité
- BHBingnan HanCorresponding
Zhejiang Sci-Tech University
- HFHongming FangCorresponding
The First People's Hospital of Xiaoshan District, Hangzhou
Topics & keywords
- Angiogenesis
- Vascular endothelial growth factor
- Medicine
- VEGF receptors
- Cancer research
- Tyrosine kinase
- Pharmacology
- Receptor tyrosine kinase
- Good health and well-being